

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Yoshio MIKI et al.)	Group Art Unit: 1634
)	
Application No.: 10/578,077)	Examiner: Diana B. JOHANNSEN
)	
§371(c) Date: May 8, 2007)	
International Filing Date: November 5, 2004)	
)	
For: METHOD AND KIT FOR)	Confirmation No. 3057
PREDICTING ADVERSE SIDE)	
EFFECTS OF PACLITAXEL)	
THERAPY)	

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO SUPPLEMENTARY SPECIES ELECTION REQUIREMENT

Applicants now respond to the Office Action mailed August 12, 2010.


In the Office Action, the Examiner requires election of one of the 5 different CYP2C8 polymorphisms set forth in claim 6 (polymorphisms in the five sequences of SEQ ID NOs: 1, 2, 3, 4, and 5), or one combination of those polymorphisms, as a single species. Office Action at page 3.

Applicants elect the "genetic polymorphism at the 11th nucleotide of the sequence defined by SEQ ID NO: 4 in CYP2C8 gene" as a species of CYP2C8 polymorphism for further prosecution. Claims 1 and 4-9 read on the elected species.

Please grant any extensions of time required to enter this response and charge
any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.



Dated: September 10, 2010

By: _____
Bing Hai, Ph.D.
Reg. No. 57,170
(650) 849-6774